Preparing BBI-001 as an oral, non-absorbed iron chelator for prevention of iron overload
将 BBI-001 制备为口服非吸收铁螯合剂,用于预防铁过载
基本信息
- 批准号:10258539
- 负责人:
- 金额:$ 29.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAge-MonthsAnimal ModelAnimalsBindingBiological SciencesChelation TherapyChemistryChronicChronic CareCirrhosisClinicalDataDietary IronDiseaseDoseEnterobactinEuropeEuropeanFecesFerritinGastrointestinal tract structureGelGenetic DiseasesGoalsHealthHealth Care CostsHeart failureHereditary hemochromatosisInterventionInvestigational DrugsInvestigational New Drug ApplicationIronIron Chelating AgentsIron OverloadIron binding capacity measurementKineticsLegal patentMaintenanceMaximum Tolerated DoseMusOralOrganOutcomeOutputPathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePharmacological TreatmentPharmacologyPhasePhase Ib Clinical TrialPolymersPreparationPreventionPublishingRattusRiskSafetySerumSeveritiesSmall Business Innovation Research GrantSmall IntestinesStructureTimeTissuesToxic effectTranslatingUnited StatesVenous blood samplingabsorptionbasecGMP productionclinical translationcommercial applicationcostcrosslinkdesignenzyme replacement therapyexperiencegene therapyhepcidinimprovediron absorptioniron chelation therapymeetingspre-clinicalpreclinical efficacypreclinical safetyside effectstandard of caretechnological innovation
项目摘要
PROJECT SUMMARY/ABSTRACT
Hereditary Hemochromatosis (HH) is one of the most common genetic disorders in the United States affecting
1 million people primarily of Northern European descent. People with HH are unable to produce hepcidin and,
as a result, experience excess absorption of dietary iron. Excess iron is stored in tissues and organs, causing
clinical iron overload and severe health issues, including cirrhosis and heart failure. Phlebotomy is the primary
treatment for managing serum ferritin levels in patients with HH, with patients requiring maintenance
phlebotomy treatments 4-6 times per year on average throughout their lifetime. While phlebotomy is safe, it is
not well tolerated by patients. This leads to poor long-term compliance, significant organ damage, and
increased risk of severe health conditions. Pharmacologic treatment offers an attractive alternative to
maintenance phlebotomy. However, while studies have explored the potential of pharmacologic interventions
for iron overload (e.g., systemic iron chelation therapy, protein replacement therapy, gene therapy), few have
been clinically translated and none have been commercialized for chronic management of iron overload due
to issues of safety and cost. As a result, there is a significant need for a safe, convenient intervention that is
an effective alternative to phlebotomy for chronic maintenance of iron overload in patients with HH. In this
project, we will develop an orally dosed, non-absorbed iron chelator, BBI-001, that binds dietary iron in the
small intestine and eliminates it through fecal output for chronic maintenance of serum ferritin levels in
patients with HH. Preliminary studies of BBI-001 have validated its mechanism of action in a small animal
model and demonstrated that it is non-absorbed and has high iron binding capacity, and selectivity with rapid
kinetics for binding iron prior to absorption in the gastrointestinal tract. This Phase I SBIR study has two
Specific Aims: In Specific Aim 1, we will complete a preclinical Maximum Tolerated Dose toxicity study in rats
to validate BBI-001’s safety when multiple doses are given per day. Specific Aim 2 will focus on rapid clinical
translation of BBI-001 by preparing a package to support a pre-IND (Investigational New Drug) meeting with
the FDA for BBI-001 and by advancing Chemistry, Manufacturing, and Controls (CMC) strategy in preparation
for cGMP production. The long-term goal of this project is to commercialize BBI-001 as the first and only non-
toxic iron chelation therapy and a safe and effective alternative to maintenance phlebotomy for chronic
maintenance of serum ferritin levels in HH patients. Chronic treatment of iron overload in HH patients with
BBI-001 will result in improved compliance and more consistent maintenance of serum ferritin levels, leading
to lower risk of organ damage and related complications, reduced healthcare costs, and improved long-term
outcomes in patients with HH.
项目总结/摘要
遗传性血色病(HH)是美国最常见的遗传性疾病之一,
100万人主要是北方欧洲人的后裔。患有HH的人不能产生hepcidin,
结果,经历了膳食铁的过量吸收。过量的铁储存在组织和器官中,
临床铁超载和严重的健康问题,包括肝硬化和心力衰竭。静脉切开术是主要的
用于管理HH患者血清铁蛋白水平的治疗,患者需要维持治疗
在其一生中,平均每年进行4-6次静脉切开术治疗。虽然放血术是安全的,
患者不能很好地耐受。这导致长期依从性差,严重的器官损伤,
严重健康状况的风险增加。药物治疗提供了一个有吸引力的替代方案,
维持性静脉切开术然而,尽管研究已经探索了药物干预的潜力,
对于铁过载(例如,全身性铁螯合疗法、蛋白质替代疗法、基因疗法),很少有
已被临床转化,但尚未商业化用于长期管理铁超载,
安全和成本的问题。因此,非常需要一种安全、方便的干预措施,
是HH患者长期维持铁超负荷的一种有效的静脉切开术替代方法。在这
项目,我们将开发一种口服剂量,非吸收铁螯合剂,BBI-001,结合膳食铁在
小肠和消除它通过粪便输出慢性维持血清铁蛋白水平,
患者HH。BBI-001的初步研究已经在小动物中验证了其作用机制
模型,并证明它是非吸收,具有高铁结合能力,选择性与快速
在胃肠道吸收之前结合铁的动力学。第一阶段SBIR研究有两个
具体目标:在具体目标1中,我们将完成大鼠临床前最大耐受剂量毒性研究
验证BBI-001在每天多次给药时的安全性。具体目标2将侧重于快速临床
翻译BBI-001,准备一个文件包,以支持IND(研究性新药)前会议,
FDA的BBI-001,并通过推进化学,制造和控制(CMC)战略的准备
用于cGMP生产。该项目的长期目标是将BBI-001商业化,作为第一个也是唯一一个非
毒性铁螯合疗法和维持性静脉切开术的一种安全有效的替代方法
维持HH患者的血清铁蛋白水平。HH患者铁超负荷的长期治疗
BBI-001将改善依从性,更一致地维持血清铁蛋白水平,
降低器官损伤和相关并发症的风险,降低医疗费用,改善长期
HH患者的结局。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cory Berkland其他文献
Cory Berkland的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cory Berkland', 18)}}的其他基金
Engineering Microparticles for Taste-Masking and Controlled Release of Pediatric
用于儿科药物掩味和控释的工程微粒
- 批准号:
8396082 - 财政年份:2012
- 资助金额:
$ 29.94万 - 项目类别:
Precision Particle Fabrication-enabled Betamethasone-loaded Microspheres for Tran
用于 Tran 的精密颗粒制造负载倍他米松的微球
- 批准号:
8396087 - 财政年份:2012
- 资助金额:
$ 29.94万 - 项目类别:
Integrative colloidal gels for cranial defect repair
用于颅骨缺损修复的一体化胶体凝胶
- 批准号:
8433328 - 财政年份:2012
- 资助金额:
$ 29.94万 - 项目类别:
Integrative colloidal gels for cranial defect repair
用于颅骨缺损修复的一体化胶体凝胶
- 批准号:
8239401 - 财政年份:2012
- 资助金额:
$ 29.94万 - 项目类别:
Targeted nanoscale antigen arrays for treating autoimmune diseases
用于治疗自身免疫性疾病的靶向纳米级抗原阵列
- 批准号:
8513574 - 财政年份:2012
- 资助金额:
$ 29.94万 - 项目类别:
Integrative colloidal gels for cranial defect repair
用于颅骨缺损修复的一体化胶体凝胶
- 批准号:
8804184 - 财政年份:2012
- 资助金额:
$ 29.94万 - 项目类别:
Integrative colloidal gels for cranial defect repair
用于颅骨缺损修复的一体化胶体凝胶
- 批准号:
8607930 - 财政年份:2012
- 资助金额:
$ 29.94万 - 项目类别:
Multi-day Pain Management Therapy with Novel Injectable Formulation
采用新型注射制剂的多日疼痛管理疗法
- 批准号:
8198342 - 财政年份:2011
- 资助金额:
$ 29.94万 - 项目类别:
Expanding Precision Particle Fabrication Technology for the Widespread Control of
扩展精密粒子制造技术以实现广泛控制
- 批准号:
7908631 - 财政年份:2010
- 资助金额:
$ 29.94万 - 项目类别:
Expanding Precision Particle Fabrication Technology for the Widespread Control of
扩展精密粒子制造技术以实现广泛控制
- 批准号:
8089561 - 财政年份:2010
- 资助金额:
$ 29.94万 - 项目类别: